



1. A peptide of the formula:



2. The peptide of claim 1, wherein R<sub>1</sub> is Asn-Pro-Val- and R<sub>2</sub> is hydrogen or hydroxy.
3. The peptide of claim 1, wherein R<sub>1</sub> is Pro-Val- and R<sub>2</sub> is -Val.
4. The peptide of claim 1, wherein R<sub>1</sub> is Val- and R<sub>2</sub> is -Val-Thr.
5. The peptide of claim 1, wherein R<sub>1</sub> is hydrogen or hydroxy and R<sub>2</sub> is -Val-Thr-Pro.
6. The peptide of claim 1, wherein R<sub>1</sub> is Lys-Ser-His-Gly-Arg-Thr-Gln-Asp-Glu-Asn-Pro-Val- and R<sub>2</sub> is -Val-Thr.


7. A pharmaceutical composition containing as an active ingredient a peptide of the formula:



and salts thereof, wherein  $R_1$  and  $R_2$  are independently selected from the group consisting of hydrogen, hydroxy, an amino acid residue and a polypeptide residue; provided that  $R_1$  and  $R_2$  are not both hydrogen or hydroxyl at the same time; including substitutions, additions or deletions thereof provided that said peptide is capable of neutralizing or modulating the production of anti-myelin basic protein, alone or in combination, in admixture with a pharmaceutical acceptable carrier.

8. The composition of claim 7, wherein  $R_1$  is Asn-Pro-Val- and  $R_2$  is hydrogen or hydroxy.
9. The composition of claim 7, wherein  $R_1$  is Pro-Val- and  $R_2$  is -Val.
10. The composition of claim 7, wherein  $R_1$  is Val- and  $R_2$  is -Val-Thr.
11. The composition of claim 7, wherein  $R_1$  is hydrogen or hydroxy and  $R_2$  is -Val-Thr-Pro.
12. The composition of claim 7, wherein  $R_1$  is Lys-Ser-His-Gly-Arg-Thr-Gln-Asp-Glu-Asn-Pro-Val- and  $R_2$  is -Val-Thr.

13. A method of treating multiple sclerosis in a human by administering to a patient in need thereof, an effective amount of a peptide of the formula:



and salts thereof, wherein  $R_1$  and  $R_2$  are independently selected from the group consisting of hydrogen, hydroxy, an amino acid residue and a polypeptide residue; provided that  $R_1$  and  $R_2$  are not both hydrogen or hydroxyl at the same time; including substitutions, additions or deletions thereof provided that said peptide is capable of neutralizing or modulating the production of anti-myelin basic protein, alone or in combination, in admixture with a pharmaceutical acceptable carrier.

14. The method of claim 13, wherein  $R_1$  is Asn-Pro-Val- and  $R_2$  is hydrogen or hydroxy.
15. The method of claim 13, wherein  $R_1$  is Pro-Val- and  $R_2$  is -Val.
16. The method of claim 13, wherein  $R_1$  is Val- and  $R_2$  is -Val-Thr.
17. The method of claim 13, wherein  $R_1$  is hydrogen or hydroxy and  $R_2$  is -Val-Thr-Pro.
18. The method of claim 13, wherein  $R_1$  is Lys-Ser-His-Gly-Arg-Thr-Gln-Asp-Glu-Asn-Pro-Val- and  $R_2$  is -Val-Thr.
19. The method of claim 13, wherein the peptide is administered intravenously, intrathecally, orally or a combination thereof.
20. The method of claim 19, wherein the peptide is administered intravenously at a dose ranging from 1 mg/kg of body weight to 10 mg/kg of body weight, in single or sequential dosage, as may be required.

05613383 032004

